A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
Open Access
- 15 April 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 98 (8), 1320-1326
- https://doi.org/10.1038/sj.bjc.6604300
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2007
- Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 daysCancer Science, 2005
- Phase II study of E7070 in patients with metastatic melanomaAnnals of Oncology, 2005
- Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4‐benzenedisulphonamide) in human plasma, urine and faeces by high‐performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryRapid Communications in Mass Spectrometry, 2004
- 420 The combination of Indisulam (E7070) with cisplatin, oxaliplatin and 5-fluorouracil are synergistic in vitro and in vivoEuropean Journal of Cancer Supplements, 2004
- A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research, 2004
- Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in ratsJournal of Pharmacy and Pharmacology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- An Adverse Interaction between Warfarin and 5-Fluorouracil: A Case Report and Review of the LiteratureChemotherapy, 1999
- Cancer Cell CyclesScience, 1996